Following adults with alopecia areata under dermatology care over time
Follows adults with alopecia areata to learn about safety and effectiveness of care.
Key facts
- Who runs it
- CorEvitas
- Where
- Waltham, United StatesSee the site
- Trial code
- Registry title
- CorEvitas Alopecia Areata (AA) Safety and Effectiveness Registry
- Status
- Recruiting
- People taking part
- 5,000 people, planned
- Started
- 25 Oct 2022
- Expected to end
- 31 Dec 2099
- Type of study
- Observational
- Record updated
- 9 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with alopecia areata (patchy hair loss) cared for by a dermatology provider. It is an observational registry that follows people over time.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Alopecia areata diagnosed by a dermatologist or a qualified dermatology practitioner.
- Earlier treatment
- People must be prescribed or starting a medication allowed by the registry at the time they join.
Main reasons for not taking part
- Taking part, or planning to take part, in a double-blind randomized trial of an alopecia areata drug
- Not willing to give personal information
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- A subject must meet all the following criteria to participate in the registry:; Has been diagnosed with alopecia areata by a dermatologist or a qualified dermatology practitioner; Is at least 18 years of age or older; Is willing to provide Personal Information; Is prescribed or starting an Enrollment Eligible Medication at the time of enrollment
Who cannot take part
- Any of the following would exclude the subject from participating in the registry:; Is participating or planning to participate in a double-blind randomized trial for an AA drug. Note:; Concurrent participation in another observational registry or open-label Phase 3b/4 trial is allowed
Where in United States
- CorEvitas, LLCWaltham, United StatesContact: Jeffrey GreenbergTaking people
About the trial
What the trial wants to find out
Prospective, observational cohort study for subjects with AA under the care of a dermatology provider. Approximately 5,000 subjects and 100 clinical sites in North America will be recruited to participate with no defined upper limit for either target.
The group in the trial
- Alopecia Areata
Pts presenting to enrolling sites across the US are invited to enroll if eligible
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- CorEvitas Alopecia Areata (AA) Safety and Effectiveness Registry
- Plain-language title
- Following adults with alopecia areata under dermatology care over timeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 9 February 2026